Fig. 7: Dynamic serological proteomic signatures and biomarker panels for monitoring fibrosis regression in on-treatment CHB patients. | Nature Communications

Fig. 7: Dynamic serological proteomic signatures and biomarker panels for monitoring fibrosis regression in on-treatment CHB patients.

From: Serological proteomic characterization for monitoring liver fibrosis regression in chronic hepatitis B patients on treatment

Fig. 7

Prolonged AVT induced progressive serological proteomic and functional shifts in both fibrosis regressors and non-regressors. Notably, serological proteomic recovery was more pronounced in fibrosis regressors compared to non-regressors following long-term AVT. Additionally, a seven-protein panel was identified for monitoring fibrosis regression during short-term AVT, while a three-protein panel was established for long-term AVT. Abbreviations: AVT antiviral therapy, CHB chronic hepatitis B, DAP differentially abundant protein, NR non-regressor, R regressor.

Back to article page